Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash & Equivalents for 10 consecutive years, with $54.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 39.08% to $54.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.3 million through Dec 2025, down 39.08% year-over-year, with the annual reading at $54.3 million for FY2025, 39.08% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $54.3 million at Rhythm Pharmaceuticals, down from $416.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $416.1 million in Q3 2025, with the low at $48.0 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $111.6 million, with a median of $90.9 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents crashed 64.99% in 2023, then surged 767.18% in 2025.
  • Over 5 years, Cash & Equivalents stood at $59.6 million in 2021, then surged by 114.86% to $128.0 million in 2022, then tumbled by 52.81% to $60.4 million in 2023, then surged by 47.56% to $89.1 million in 2024, then crashed by 39.08% to $54.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $54.3 million, $416.1 million, and $136.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.